$50.2 M

ITEK Mkt cap, 22-Dec-2017
Inotek Pharmaceuticals Net income (Q3, 2018)-16.1 M
Inotek Pharmaceuticals EBIT (Q3, 2018)-15.3 M
Inotek Pharmaceuticals Cash, 30-Sep-201838.1 M

Inotek Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

R&D expense

12.6m32.0m14.2m

General and administrative expense

7.8m9.9m12.5m

Operating expense total

20.4m41.9m26.7m

EBIT

(20.4m)(41.9m)(26.7m)

Interest expense

1.2m1.4m3.6m

Interest income

89.0k443.0k819.0k

Net Income

(68.0m)(42.9m)(29.5m)

Inotek Pharmaceuticals Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

80.0m29.8m78.7m

Inventories

1.1m1.9m

Current Assets

112.4m128.3m101.0m

PP&E

812.0k1.1m563.0k

Total Assets

113.3m129.6m101.8m

Accounts Payable

1.6m1.6m451.0k

Current Liabilities

4.1m7.2m4.1m

Total Liabilities

56.5m54.0m

Additional Paid-in Capital

304.6m311.8m316.1m

Retained Earnings

(196.0m)(238.9m)(268.4m)

Total Equity

108.8m73.2m47.8m

Financial Leverage

1 x1.8 x2.1 x

Inotek Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(68.0m)(42.9m)(29.5m)

Depreciation and Amortization

45.0k169.0k200.0k

Accounts Payable

487.0k(41.0k)(1.1m)

Cash From Operating Activities

(17.4m)(37.3m)(26.1m)

Purchases of PP&E

(412.0k)(487.0k)(70.0k)

Cash From Investing Activities

(31.7m)(66.1m)75.0m

Short-term Borrowings

(5.8m)(5.8m)

Cash From Financing Activities

125.5m53.1m

Interest Paid

89.0k89.0k3.0m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(1.5m)(3.8m)(56.0m)(10.1m)(18.8m)(29.9m)(10.7m)(17.2m)(24.6m)(15.3m)(31.1m)(47.2m)

Depreciation and Amortization

1.0k6.0k37.0k72.0k111.0k61.0k124.0k162.0k83.0k157.0k233.0k

Accounts Payable

154.0k(333.0k)563.0k(257.0k)(712.0k)144.0k310.0k(1.2m)(1.2m)(2.3m)1.3m2.7m

Cash From Operating Activities

(2.0m)(6.0m)(10.4m)(9.0m)(17.0m)(26.1m)(11.6m)(17.5m)(23.1m)(11.6m)(21.3m)(33.0m)

Purchases of PP&E

(30.0k)(318.0k)(15.0k)(236.0k)(344.0k)(53.0k)(70.0k)(70.0k)(8.0k)(117.0k)(570.0k)

Cash From Investing Activities

(30.0k)(29.4m)(12.3m)(28.7m)(23.8m)7.1m15.3m42.5m86.1m(21.3m)(24.3m)

Short-term Borrowings

(5.8m)(5.8m)(5.8m)(5.8m)(5.8m)

Long-term Borrowings

(5.8m)

Cash From Financing Activities

51.5m51.5m125.4m51.5m4.2m52.9m35.0k19.0k78.5m78.7m

Interest Paid

89.0k89.0k89.0k89.0k89.0k89.0k1.5m1.5m3.0m1.5m1.5m3.0m

Income Taxes Paid

2.0k

Inotek Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information

Inotek Pharmaceuticals Operating Metrics

FY, 2016

Patent Portfolios

1

Phase III Trials Products

1
Report incorrect company information